Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

@article{Ghiringhelli2006MetronomicCR,
  title={Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients},
  author={François Ghiringhelli and C{\'e}dric M{\'e}nard and Pierre Emmanuel Puig and Sylvain Ladoire and Stephan G. Le Roux and François Martin and {\'E}ric Solary and Axel L E Cesne and Laurence Zitvogel and Bruno Chauffert},
  journal={Cancer Immunology, Immunotherapy},
  year={2006},
  volume={56},
  pages={641-648}
}
CD4+CD25+ regulatory T cells are involved in the prevention of autoimmune diseases and in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one injection of cyclophosphamide could significantly decrease both numbers and suppressive functions of regulatory T cells, facilitating vaccine-induced tumor rejection. In humans, iterative low dosing of cyclophosphamide, referred to as “metronomic” therapy, has recently been used in patients with advanced chemotherapy… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
421 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 421 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…